Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC-Reference-Cited by-同舟云学术

Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC

Published:2014-07-08 Issue:2 Volume:35 Page:620-626
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver Int

Author:

Ricke Jens¹,Bulla Karsten¹,Kolligs Frank²,Peck-Radosavljevic Markus³,Reimer Peter⁴,Sangro Bruno⁵,Schott Eckart⁶,Schütte Kerstin⁷,Verslype Chris⁸,Walecki Jerzy⁹,Malfertheiner Peter⁷,

Affiliation:

1. Department of Radiology and Nuclear Medicine; Otto-von-Guericke University; Magdeburg Germany

2. Department of Medicine II; LMU University of Munich; Munich Germany

3. Internal Medicine III; Department of Gastroenterology & Hepatology; Medical University of Vienna; Vienna Austria

4. Department of Radiology; Karlsruhe Hospital; Karlsruhe Germany

5. Liver Unit and HPB Oncology; Clinica Universidad de Navarra; Pamplona Spain

6. Department of Hepatology and Gastroenterology; Charité University Hospital Berlin; Berlin Germany

7. Department of Gastroenterology, Hepatology and Infectious Diseases; Otto-von-Guericke University; Magdeburg Germany

8. Department of Hepatology and Digestive Oncology; University Hospital Gasthuisberg; Leuven Belgium

9. Department of Radiology; MSWiA Hospital Warsaw; Warsaw Poland

Funder

SIRTEX Medical

Bayer Healthcare

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/liv.12622/fullpdf

Reference25 articles.

1. Sorafenib in advanced hepatocellular carcinoma;Llovet;N Engl J Med,2008

2. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial;Cheng;Lancet Oncol,2009

3. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma;European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer;J Hepatol,2012

4. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival;Llovet;Hepatology,2003

5. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes;Salem;Gastroenterology,2010

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Portal hypertension increases the risk of hepatic decompensation after 90Yttrium radioembolization in patients with hepatocellular carcinoma: a cohort study;Therapeutic Advances in Gastroenterology;2023-01

2. Summary of key guidelines for locoregional treatment of HCC in Asia, Europe, South and North America;The British Journal of Radiology;2022-10-01

3. Clinical consensus statement: Selective internal radiation therapy with yttrium 90 resin microspheres for hepatocellular carcinoma in Asia;International Journal of Surgery;2022-06

4. Safety and Efficacy of¹⁶⁶Ho Radioembolization in Hepatocellular Carcinoma: The HEPAR Primary Study;Journal of Nuclear Medicine;2022-05-19

5. Extrahepatic Disease in Hepatocellular Carcinoma: Do We Always Need Whole-Body CT or Is Liver MRI Sufficient? A Subanalysis of the SORAMIC Trial;Biomedicines;2022-05-18